13 results about "Brain tissue injury" patented technology

The invention provides a rigidity-flexibility variable multifunctional optical genetic implantable probe and a preparation method thereof. The probe comprises a thin film electrode layer and a rigidity-flexibility variable shape memory layer arranged at the bottom of the thin film electrode layer. The micro LED is integrated in the flexible nerve probe through contact type laser transfer printing to serve as a light stimulation light source, the preparation success rate is remarkably increased, heat radiated outwards during light stimulation is reduced, and damage to brain tissue of the brain caused by high-Young-modulus optical fibers is avoided; meanwhile, a rigid-flexible variable shape memory layer is also integrated, so that the Young modulus of the probe is high when the in-vitro temperature is relatively low, fixed-point implantation can be directly carried out without an auxiliary tool, the Young modulus of the probe is reduced along with the rise of the body temperature after the probe is implanted into the body, and the probe finally adapts to the mechanical tissue strength of the brain; therefore, the implantation efficiency and the mechanical adaptability of the probe to brain tissues are improved, and micron-scale accurate implantation of the probe, neuron-scale positioning of electrical stimulation and light stimulation points and long-term stable recording of electrophysiological signals are realized.

The scheme provides a kind of engineered exosome double drug delivery system loaded with ergosterol and its preparation method and application, belongs to the field of nanomaterials and nanobiomedicine, based on the innovative ROS-responsive nanomaterial CHPG design, load the active ingredient ergosterol to play the role of treatment and repair, which realizes the blood-brain barrier penetration and precise drug release in lesion area through targeted functional modification;It is wrapped in the nasal mucosa-derived stem cell exosome to form a drug delivery system Exo@Erg-CHPG-M, which combines the natural biological characteristics of exosome and the precise targeting advantage of nanomicelle, significantly improves the drug delivery efficiency, in vitro and animal model verification show that, the system can improve the neurological impairment and brain tissue injury after ischemic stroke by synergistically regulating inflammation and neural repair pathways, the scheme provides a new technical scheme for the precise treatment of central nervous system diseases such as cerebral stroke.

The invention relates to the technical field of medicines, in particular to application of DP-b99 and a derivative thereof in preparation of a medicine for treating cerebral ischemia mechanical thrombus extraction reperfusion injury. On the basis of mechanical thrombus extraction and reperfusion of cerebral ischemia, DP-b99 is combined to reduce mechanical thrombus extraction and reperfusion injury of cerebral arterial thrombosis, so that the inflammation level of brain tissues can be reduced, the volume of cerebral infarction can be reduced, the injury of the brain tissues can be effectively reduced, and the treatment effect is remarkable.

This invention discloses a method, apparatus, device, medium, and medical system for determining brain surgical pathways. The method involves acquiring a brain structure model of a target user and at least one target point; determining the information transmission relationship between each nucleus sub-model and each neural fiber sub-model based on the brain structure model; determining multiple candidate surgical plans based on multiple preset path starting points, the target nucleus sub-model to which at least one target point belongs, and the information transmission relationship; evaluating the quality of each candidate surgical plan using a quantitative evaluation model based on at least one evaluation dimension, and determining the path quality attributes corresponding to each candidate surgical plan; determining at least one recommended surgical plan based on each path quality attribute; automatically generating multiple candidate paths that conform to neural conduction characteristics; and selecting the optimal plan through a quantitative evaluation model. This approach improves surgical accuracy while effectively reducing the risk of brain tissue damage and the complexity of surgical procedures.

The invention relates to the technical field of medical devices, in particular to a medical device special for long-term drug delivery of skull marrow and a use method. According to the technical scheme, the skull drilling device comprises a drill rod for drilling a hole in a skull, the outer ring of the drill rod is sleeved with a first positioning sleeve, and the first positioning sleeve is used for limiting the drilling depth and preventing the skull from being drilled through to cause brain tissue damage; the dosing tube is used for dosing into the drill hole, one end of the dosing tube is fixed in the drill hole, a second positioning sleeve is arranged on the outer ring of the dosing tube in a sleeving manner, and the second positioning sleeve is used for limiting the depth of the dosing tube entering the drill hole. The skull bone marrow long-term stable drug delivery can be achieved, the limitation of the blood brain barrier on drug delivery is broken through, clinical transformation of an efficient drug delivery pathway is promoted, and the treatment effect of central nervous system diseases is improved.

This application belongs to the field of traditional Chinese medicine technology and relates to a traditional Chinese medicine composition for treating cerebral infarction. The traditional Chinese medicine composition of this application comprises the following raw materials in parts by weight: Ligusticum chuanxiong, Astragalus membranaceus, Pueraria lobata, Uncaria rhynchophylla, and a compound fungus; the traditional Chinese medicine composition is prepared by the following method: S1, Ligusticum chuanxiong, Astragalus membranaceus, Pueraria lobata, and Uncaria rhynchophylla are pulverized and the active ingredients are extracted by water extraction and alcohol precipitation to obtain an extract; S2, the compound fungus is pulverized, extracted by boiling with deionized water at normal pressure, and then fermented with fermenting bacteria in a sealed container to obtain a fermentation liquid; S3, the extract and fermentation liquid are combined, concentrated under reduced pressure, and spray-dried to obtain the traditional Chinese medicine composition. This application has a simple formula and safe ingredients. Through multiple effects such as promoting blood circulation and removing blood stasis, tonifying qi and strengthening the exterior, clearing heat and detoxifying, dilating blood vessels, and calming the liver and extinguishing wind, it jointly promotes cerebral blood circulation, reduces brain tissue damage, and promotes nerve cell repair and regeneration, showing broad clinical application prospects.

The application provides application of IL-17A as a target point in preparation of a drug for screening treatment or prevention of cardiac arrest. The application also provides application of IL-17A as a target point in preparation of a monoclonal antibody drug for screening treatment or prevention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving post-cardiac arrest syndrome. The application provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for early intervention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving myocardial injury, cardiac dysfunction, brain injury or neurological dysfunction caused by cardiac arrest. The application also provides application of a reagent for detecting IL-17A level in serum in preparation of a kit for detecting a myocardial infarction combined with cardiac arrest patient. The application proves by experiments that IL-17 related pathways in heart and brain tissues are significantly activated after cardiac arrest, and IL-17A in serum is significantly increased, and early antagonism of IL-17A by using an IL-17A monoclonal antibody after resuscitation can improve myocardial injury, cardiac dysfunction (systolic and diastolic dysfunction), brain tissue injury or neurological dysfunction after cardiac arrest, and improve survival rate after cardiac arrest.

The invention relates to the technical field of biology, in particular to a medicine and application thereof. The drug is an exosome (DPSCs-Exos) derived from dental pulp stem cells (DPSCs-Exos). The DPSCs-Exos is given after acute cerebral apoplexy, so that sensory movement and cognitive function recovery after cerebral ischemia can be promoted. The DPSCs-Exos can improve ischemia for 45 minutes, and brain tissue injury and neurological function injury of animals after reperfusion for 28 days. The DPSCs-Exos promotes the expression increase of protein arginine methyltransferase (PRMT5) in oligodendroglia precursor cells (OPC), inhibits the expression of a differentiation inhibition factor 2 (ID2) through nucleation, promotes the OPCs to proliferate and differentiate into oligodendroglia cells (OL), and promotes the integrity repair of white matter. In addition, DPSCs-Exos can promote proliferation and migration of vascular endothelial cells and promote blood brain barrier repair.

The utility model discloses a deep brain long needle electrode, which comprises a needle body, at least one connecting part and a contact assembly, the connecting part is detachably connected with the needle body, the contact assembly comprises a flexible part and a plurality of electric contacts, the flexible part is connected with the at least one connecting part and can wrap or fall off the outer surface of the needle body, and the electric contacts are electrically connected with the flexible part. The plurality of electric contacts are distributed at intervals along the surface of the flexible part and are connected to the flexible part. The utility model can effectively solve the problems that the diameter of the whole probe is increased due to the fact that a large number of conductive wires are needed for increasing the number of channels, and brain tissues are damaged due to the increased diameter of the probe.

The application provides a Pediococcus pentosaceus strain NCU16V with thrombus prevention and cerebral ischemic injury prevention, a microbial inoculum containing the same and application, and relates to the technical field of microorganisms.The preservation number of the Pediococcus pentosaceus strain NCU16V is CGMCC No.35427.The Pediococcus pentosaceus strain NCU16V has good gastrointestinal digestion tolerance, and has a high survival rate after being digested in simulated artificial gastric juice and intestinal juice for 3 hours, as verified by the research of the application.Meanwhile, it is verified that the Pediococcus pentosaceus strain NCU16V and the microbial inoculum containing the same can be widely applied in drugs for preventing thrombosis, drugs for relieving brain tissue injury after cerebral ischemia and preparation of ginkgo fermented products with thrombosis prevention.

This invention relates to the application of compound ID-8 in the preparation of drugs for treating ischemic cerebrovascular diseases. This invention demonstrates the protective effect of ID-8 on ischemic brain. Research data shows that ID-8 can significantly reduce brain tissue damage and cell death caused by ischemic stroke, shrink infarct foci, and improve neurological function. Compound ID-8 can be used to prepare drugs for treating ischemic cerebrovascular diseases, can be combined with various excipients, can be combined with various existing drugs for treating ischemic cerebrovascular diseases, and is applicable to various dosage forms and routes of administration. This results in novel, safe, and effective drugs and treatments for ischemic cerebrovascular diseases that can reduce brain ischemia-related damage, and has significant clinical and social value.

The invention discloses application of sulodexide in preparation of a medicine for treating sepsis-related encephalopathy, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, the effect of preventing and / or treating sepsis-related encephalopathy of sulodexide is found for the first time; animal experiments prove that sulodexide improves cognitive impairment of a patient with sepsis-related encephalopathy by improving the survival rate of the patient with sepsis-related encephalopathy, inhibits brain neuroinflammation of the patient with sepsis-related encephalopathy, reduces brain tissue damage of the patient with sepsis-related encephalopathy, and improves the curative effect of the patient with sepsis-related encephalopathy. According to the present invention, with the application of the compound in the prevention and / or treatment of the sepsis-related encephalopathy, the microglial cell excitation of the sepsis-related encephalopathy patient can be inhibited, and the HMGB1 and / or RAGE pathway of the sepsis-related encephalopathy patient can be inhibited so as to prevent and / or treat the sepsis-related encephalopathy, such that the new idea is provided for the preparation of the sepsis-related encephalopathy product, and the wide application prospect is provided.

The present invention relates to a compound of formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a polymorph, a prodrug, an isotope, or a co-crystal thereof, or a pharmaceutically acceptable salt thereof, (I) wherein A, R1, and R2 are as defined in the description and claims. The present invention also relates to a pharmaceutical composition comprising a compound according to the invention, and a pharmaceutical acceptable carrier. The present invention also relates to the present compounds for use as a medicine and / or as diagnostics. The present invention also relates to the present compounds for use in the prevention and / or treatment of GPR17 mediated disorders, such as for example a disorder or syndrome selected from a myelination disorder and a disorder or syndrome associated with brain tissue damage.